SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-009674
Filing Date
2022-05-12
Accepted
2022-05-12 16:14:27
Documents
14
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amlx-20220512.htm   iXBRL 8-K 63811
2 EX-99.1 amlx-ex99_1.htm EX-99.1 151535
3 GRAPHIC img212534189_0.jpg GRAPHIC 631
  Complete submission text file 0000950170-22-009674.txt   350868

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amlx-20220512.xsd EX-101.SCH 2484
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amlx-20220512_pre.xml EX-101.PRE 11463
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amlx-20220512_lab.xml EX-101.LAB 13996
8 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20220512_htm.xml XML 4882
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

IRS No.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 22917962
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences